GILL DAVID N
Insider CIK 1106519 · SSKN Director · HSGX Director · CEMP Director · EOLS Director · GI President and CFO · SBBP Director · YMAB Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| EOLS Evolus, Inc. | A Award | 2026-02-17 | 2026-02-19 | 45,559 | — | $0 | 86,887 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-18 | 24,000 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-18 | 11,000 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-18 | 11,000 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-18 | 16,000 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-18 | 13,950 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-18 | 16,000 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-18 | 33,450 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer deriv | 2025-09-16 | 2025-09-18 | 14,545 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer | 2025-09-16 | 2025-09-18 | 25,080 | — | $0 | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | D To issuer | 2025-09-16 | 2025-09-18 | 5,825 | $8.60 | $50.1K | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2025-06-30 | 2025-07-02 | 33,450 | — | $0 | 33,450 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award | 2025-06-30 | 2025-07-02 | 25,080 | — | $0 | 30,905 | SEC↗ |
| EOLS Evolus, Inc. | A Award deriv | 2025-03-07 | 2025-03-11 | 11,146 | — | $0 | 11,146 | SEC↗ |
| EOLS Evolus, Inc. | A Award | 2025-03-07 | 2025-03-11 | 7,364 | — | $0 | 41,328 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2024-06-11 | 2024-06-13 | 14,545 | — | $0 | 14,545 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award | 2024-06-11 | 2024-06-13 | 3,495 | — | $0 | 5,825 | SEC↗ |
| EOLS Evolus, Inc. | S Sale | 2024-05-14 | 2024-05-15 | 6,718 | $12.60 | $84.6K | 33,964 | SEC↗ |
| EOLS Evolus, Inc. | S Sale | 2024-05-13 | 2024-05-15 | 3,643 | $12.72 | $46.3K | 40,682 | SEC↗ |
| EOLS Evolus, Inc. | A Award deriv | 2024-02-07 | 2024-02-09 | 9,377 | — | $0 | 9,377 | SEC↗ |
| EOLS Evolus, Inc. | A Award | 2024-02-07 | 2024-02-09 | 6,464 | — | $0 | 44,325 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2023-06-08 | 2023-06-09 | 13,950 | — | $0 | 13,950 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award | 2023-06-08 | 2023-06-09 | 2,330 | — | $0 | 2,330 | SEC↗ |
| EOLS Evolus, Inc. | A Award deriv | 2023-01-27 | 2023-01-31 | 11,789 | — | $0 | 11,789 | SEC↗ |
| EOLS Evolus, Inc. | A Award | 2023-01-27 | 2023-01-31 | 8,293 | — | $0 | 37,861 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2022-07-15 | 2022-07-19 | 16,000 | — | $0 | 16,000 | SEC↗ |
| EOLS Evolus, Inc. | S Sale | 2022-05-16 | 2022-05-17 | 5,000 | $13.62 | $68.1K | 29,568 | SEC↗ |
| EOLS Evolus, Inc. | S Sale | 2022-05-13 | 2022-05-17 | 5,313 | $13.10 | $69.6K | 34,568 | SEC↗ |
| EOLS Evolus, Inc. | A Award deriv | 2022-01-24 | 2022-01-26 | 22,727 | — | $0 | 22,727 | SEC↗ |
| EOLS Evolus, Inc. | A Award | 2022-01-24 | 2022-01-26 | 15,568 | — | $0 | 39,881 | SEC↗ |
| SBBP Strongbridge Biopharma plc | D To issuer | 2021-10-05 | 2021-10-06 | 78,058 | — | $0 | 0 | SEC↗ |
| SBBP Strongbridge Biopharma plc | F Tax w/h | 2021-10-01 | 2021-10-05 | 17,763 | $2.06 | $36.6K | 78,058 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2021-06-10 | 2021-06-14 | 16,000 | — | $0 | 16,000 | SEC↗ |
| SBBP Strongbridge Biopharma plc | A Award | 2021-05-18 | 2021-05-18 | 40,000 | — | $0 | 95,821 | SEC↗ |
| SBBP Strongbridge Biopharma plc | F Tax w/h | 2021-05-14 | 2021-05-17 | 19,075 | $2.35 | $44.8K | 55,821 | SEC↗ |
| EOLS Evolus, Inc. | A Award | 2021-02-05 | 2021-02-09 | 19,313 | — | $0 | 24,313 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | M Exercise deriv | 2021-01-19 | 2021-01-20 | 2,000 | — | $0 | 24,000 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | S Sale | 2021-01-19 | 2021-01-20 | 2,000 | $46.52 | $93.0K | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | M Exercise | 2021-01-19 | 2021-01-20 | 2,000 | $11.16 | $22.3K | 2,000 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | M Exercise deriv | 2020-11-18 | 2020-11-20 | 2,000 | — | $0 | 26,000 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | S Sale | 2020-11-18 | 2020-11-20 | 2,000 | $45.77 | $91.5K | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | M Exercise | 2020-11-18 | 2020-11-20 | 2,000 | $11.16 | $22.3K | 2,000 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | M Exercise deriv | 2020-11-03 | 2020-11-05 | 4,000 | — | $0 | 28,000 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | S Sale | 2020-11-03 | 2020-11-05 | 4,000 | $45.00 | $180.0K | 0 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | M Exercise | 2020-11-03 | 2020-11-05 | 4,000 | $11.16 | $44.6K | 4,000 | SEC↗ |
| SBBP Strongbridge Biopharma plc | P Buy | 2020-09-24 | 2020-09-28 | 8,000 | $2.13 | $17.0K | 74,896 | SEC↗ |
| SBBP Strongbridge Biopharma plc | F Tax w/h | 2020-09-03 | 2020-09-04 | 23,104 | $3.61 | $83.4K | 66,896 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2020-06-23 | 2020-06-24 | 16,000 | — | $0 | 16,000 | SEC↗ |
| SBBP Strongbridge Biopharma plc | A Award | 2020-05-14 | 2020-05-15 | 40,000 | — | $0 | 90,000 | SEC↗ |
| EOLS Evolus, Inc. | A Award deriv | 2020-01-23 | 2020-01-24 | 23,458 | — | $0 | 23,458 | SEC↗ |
| SSKN STRATA Skin Sciences, Inc. | A Award | 2019-11-22 | 2019-11-26 | 18,293 | — | $0 | 64,694 | SEC↗ |
| SBBP Strongbridge Biopharma plc | A Award | 2019-09-03 | 2019-09-04 | 50,000 | — | $0 | 50,000 | SEC↗ |
| EOLS Evolus, Inc. | P Buy | 2019-06-13 | 2019-06-14 | 2,000 | $13.65 | $27.3K | 5,000 | SEC↗ |
| YMAB Y-mAbs Therapeutics, Inc. | A Award deriv | 2019-06-12 | 2019-06-14 | 16,000 | — | $0 | 16,000 | SEC↗ |
| MLNT MELINTA THERAPEUTICS, INC. | A Award deriv | 2019-06-11 | 2019-06-12 | 30,000 | — | $0 | 30,000 | SEC↗ |
| EOLS Evolus, Inc. | A Award deriv | 2019-01-23 | 2019-01-25 | 14,500 | — | $0 | 14,500 | SEC↗ |
| EOLS Evolus, Inc. | P Buy | 2018-12-14 | 2018-12-17 | 3,000 | $12.77 | $38.3K | 3,000 | SEC↗ |
| HSGX HISTOGENICS CORP | A Award deriv | 2018-06-15 | 2018-06-19 | 25,000 | — | $0 | 25,000 | SEC↗ |
| MLNT MELINTA THERAPEUTICS, INC. | A Award deriv | 2018-06-12 | 2018-06-14 | 9,100 | — | $0 | 9,100 | SEC↗ |
| MLNT MELINTA THERAPEUTICS, INC. | A Award deriv | 2018-06-12 | 2018-06-14 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SSKN STRATA Skin Sciences, Inc. | A Award | 2018-06-08 | 2018-07-17 | 31,401 | — | $0 | 46,401 | SEC↗ |
| SSKN STRATA Skin Sciences, Inc. | A Award deriv | 2018-06-08 | 2018-06-11 | 26,570 | — | $0 | 26,570 | SEC↗ |
| MLNT MELINTA THERAPEUTICS, INC. | P Buy | 2018-05-25 | 2018-05-30 | 5,000 | $6.09 | $30.4K | 6,000 | SEC↗ |
| EOLS Evolus, Inc. | A Award deriv | 2018-04-24 | 2018-04-26 | 22,696 | — | $0 | 22,696 | SEC↗ |
| HSGX HISTOGENICS CORP | P Buy | 2017-08-16 | 2017-08-17 | 3,000 | $1.81 | $5.4K | 14,000 | SEC↗ |
| HSGX HISTOGENICS CORP | A Award deriv | 2017-06-13 | 2017-06-14 | 25,000 | — | $0 | 25,000 | SEC↗ |
| HSGX HISTOGENICS CORP | P Buy | 2017-05-16 | 2017-05-17 | 3,000 | $1.68 | $5.0K | 11,000 | SEC↗ |
| CEMP CEMPRA, INC. | A Award deriv | 2017-01-03 | 2017-01-05 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CEMP CEMPRA, INC. | P Buy | 2017-01-03 | 2017-01-04 | 5,000 | $2.94 | $14.7K | 5,000 | SEC↗ |
| HSGX HISTOGENICS CORP | A Award deriv | 2016-12-16 | 2016-12-19 | 10,000 | — | $0 | 10,000 | SEC↗ |
| HSGX HISTOGENICS CORP | P Buy | 2016-12-15 | 2016-12-15 | 3,000 | $1.65 | $5.0K | 8,000 | SEC↗ |
| HSGX HISTOGENICS CORP | P Buy | 2016-12-09 | 2016-12-15 | 5,000 | $1.92 | $9.6K | 5,000 | SEC↗ |
| GI EndoChoice Holdings, Inc. | D To issuer deriv | 2016-11-22 | 2016-11-23 | 53,825 | — | $0 | 0 | SEC↗ |
| GI EndoChoice Holdings, Inc. | D To issuer deriv | 2016-11-22 | 2016-11-23 | 32,230 | — | $0 | 0 | SEC↗ |
| GI EndoChoice Holdings, Inc. | D To issuer | 2016-11-22 | 2016-11-23 | 38,585 | $8.00 | $308.7K | 0 | SEC↗ |
| GI EndoChoice Holdings, Inc. | D To issuer | 2016-11-22 | 2016-11-23 | 125,445 | $8.00 | $1.00M | 0 | SEC↗ |
| GI EndoChoice Holdings, Inc. | A Award deriv | 2016-03-29 | 2016-03-31 | 32,230 | — | $0 | 32,230 | SEC↗ |
| GI EndoChoice Holdings, Inc. | A Award | 2016-03-29 | 2016-03-31 | 14,826 | — | $0 | 137,405 | SEC↗ |
| GI EndoChoice Holdings, Inc. | P Buy | 2016-03-10 | 2016-03-10 | 2,000 | $4.70 | $9.4K | 25,130 | SEC↗ |
| GI EndoChoice Holdings, Inc. | P Buy | 2016-03-07 | 2016-03-07 | 5,000 | $4.77 | $23.8K | 23,130 | SEC↗ |
| CEMP CEMPRA, INC. | A Award deriv | 2016-01-01 | 2016-01-05 | 15,000 | — | $0 | 15,000 | SEC↗ |
| GI EndoChoice Holdings, Inc. | A Award deriv | 2015-08-14 | 2015-08-17 | 53,825 | — | $0 | 53,825 | SEC↗ |
| GI EndoChoice Holdings, Inc. | A Award | 2015-08-14 | 2015-08-17 | 53,825 | — | $0 | 133,049 | SEC↗ |
| HSGX HISTOGENICS CORP | A Award deriv | 2015-06-24 | 2015-06-26 | 6,800 | — | $0 | 6,800 | SEC↗ |
| HSGX HISTOGENICS CORP | A Award deriv | 2015-02-02 | 2015-02-02 | 13,200 | — | $0 | 13,200 | SEC↗ |
| CEMP CEMPRA, INC. | A Award deriv | 2015-01-01 | 2015-01-02 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CEMP CEMPRA, INC. | A Award deriv | 2014-01-08 | 2014-01-10 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CEMP CEMPRA, INC. | A Award deriv | 2013-02-04 | 2013-02-06 | 15,000 | — | $0 | 15,000 | SEC↗ |
| CEMP CEMPRA, INC. | A Award deriv | 2012-04-02 | 2012-04-04 | 25,000 | — | $0 | 25,000 | SEC↗ |